Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index; 2 of the 19 sources its claims cite were checked for support.
Abstract
Background: Over 92 million prescriptions for benzodiazepines are dispensed in the United States annually, yet little is known about the experiences of those taking and discontinuing them. Objective: The aim of this study is to assess the experiences of those taking, tapering, or having discontinued benzodiazepines. Methods: An online survey ( n = 1207) elicited information about benzodiazepine use, including long-term use, tapering, discontinuation, and withdrawal symptoms. Results: Symptoms associated with benzodiazepine use, tapering, and discontinuation were numerous and ranged from symptoms such as anxiety, insomnia, and nervousness to digestive problems, irregular heart rhythms, uncontrollable anger, photosensitivity, balance problems, and others. When asked how benzodiazepine symptoms affected their lives, 82.9% reported work problems, 86.3% had problems with social interactions and friendships, and 88.8% had problems with fun, recreation, and hobbies. Suicidal thoughts or attempted suicide was reported by 54.4%, and 46.8% said benzodiazepines caused lost employment. Most of the respondents for whom benzodiazepines were prescribed (76.2%) stated they had not been informed that benzodiazepines were indicated for short-term use only and that discontinuation might be difficult. About a third (31.5%) reported food allergies and/or seasonal allergies that occurred only after benzodiazepine use. Conclusion: The trajectory of those who taper or discontinue benzodiazepines is unpredictable, and many patients experience a range of protracted and severe symptoms, even years after benzodiazepines were completely discontinued. Greater awareness is needed for both prescribers and patients about the potential for a difficult withdrawal from benzodiazepines.
Overview
CoChat Summary
TL;DR
An Internet survey of 1,207 benzodiazepine users found numerous severe and long-lasting symptoms during use, tapering, and after discontinuation, with substantial life impacts and suicidal thoughts reported. Most respondents said they had not been informed that benzodiazepines were indicated for short-term use only and that discontinuation might be difficult.
Key findings
- Of 1,207 finishers, 63.2% had discontinued benzodiazepines, 24.4% were tapering, and 11.3% continued on a full dose. Symptoms often persisted for years: low energy 51.6%, nervousness/anxiety/fear 50.2%, sleep disturbances 49.0%, and memory loss 44.2% were reported as lasting years.
- Life effects were common: 82.9% reported work problems, 86.3% social interaction/friendship problems, and 88.8% problems with fun, recreation, and hobbies; 54.4% reported suicidal thoughts or attempted suicide, and 46.8% said benzodiazepines caused lost employment.
- Most respondents (76.2%) said their health care providers “definitely did not” tell them benzodiazepines were intended for short-term use and discontinuation might be difficult; 5.6% said they were “probably not” given this information.
- New conditions after benzodiazepine use included food and/or seasonal allergies in 31.5%, sensitivity to food additives or other chemicals in 41.2%, autoimmune diagnosis after initiation in 18.1% versus 11.5% before, and falls/fractures beginning after starting benzodiazepines in 21.0% versus 5.9% before.
Methods
- Anonymous online survey with 19 questions covering demographics, benzodiazepine use history, symptoms, and outcomes; recruited as a convenience sample from 16 Internet sites, including benzodiazepine-related websites and 10 Facebook groups, posted three times (October 2018, November 2018, January 2019).
- Qualtrics was used to allow only one response per IP address; 1,682 individuals started the survey and 1,207 were identified as finishers, though some did not answer every question. Respondents were 71% female, 26% male, and 2% other/prefer not to state; 76.6% lived in the United States.
- Results were analyzed in SAS by a medical statistician and confirmed by an experienced data scientist using Microsoft SQL server; the article reports compliance with CROSS methodology.
Limitations
- The paper states there was no control group; recruitment was from social media and online sources dealing with benzodiazepine use and withdrawal, producing a self-selected convenience sample that may not represent all benzodiazepine users.
- The paper states that multiple-choice symptom lists may have made patients suggestible, may have led to incorrect recall or attribution of symptoms, and that nocebo effects were not accounted for; suicidal thoughts may be underreported even in an anonymous survey.
- The paper notes that Internet health-information users tend to be younger and online support-group members tend to be in worse health, so results may not be generalizable; the text also makes evident that the cross-sectional survey cannot establish causality or true incidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 16 Not checked · 60 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, those who use the Internet for health information tend to be younger, 22 and those who join online support groups for medical conditions tend to be in generally worse health. 23”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Discussion/conclusion
What the sources say
- Supportedcites [23] Owen J Boxley M Goldstein M, et al. Use of health-related online support groups: population data from the California Health Interview Survey Complementary and Alternative Medicine Study. J Comput Mediat Commun 2010; 15: 427– 446. source
The Discussion (p. n/a, indexed passage 8) states that "those with fair or poor health were significantly more likely to use OSG and to use them with greater frequency" and that "those with the worst health status use online groups more frequently than those with better health." The Introduction likewise anticipated illness factors (physical and psychological health) as predictors of OSG use, and the Results section reports health status among the factors associated with OSG use in the CHIS-CAM sample. This directly supports the paraphrase that OSG joiners tend to be in worse health. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In an epidemiological study in Colorado from 2015 to 2017, 20% of the 3465 suicides in that period were decedents who had a recent benzodiazepine exposure.”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Discussion/conclusion
What the sources say
- Supportedcites [21] Ghosh T Bol K Butler M, et al. Epidemiologic assessment of benzodiazepine exposure among suicide deaths in Colorado, 2015-2017. BMC Public Health 2020; 20: 1149. PMC7374952 32698851 source
The Abstract Results (Colorado, 2015-2017) state 'Among the 3465 suicide deaths in Colorado between 2015 and 2017, 20% had recent benzodiazepine exposure,' and the Results section repeats it ('One-fifth (20%) of all suicide deaths had recent benzodiazepine exposure (Table 1)'), with the Methods defining recent exposure as a prescription within 30 days of death or positive post-mortem toxicology. Population, period, denominator and proportion all match the citing sentence. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of those who had tapered, 4.4% took >2 years to taper and 6.0% tapered for more than 1 but less than 2 years.”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Symptoms
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, a wide range of other symptoms, including photosensitivity, gastrointestinal problems, food allergies, cutaneous symptoms, cephalgia, problems with balance, and others, were reported.”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Discussion/conclusion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Highly sensitive airways were reported by 30.1% only after benzodiazepine use.”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > New medical conditions not previously experienced
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 17 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a convenience sample of 1,200 individuals recruited through several patient-facing internet and social media sites with content tailored to patients facing challenges with BZD discontinuation, Reid Finlayson et al.128 found that 54% of respondents reported suicidal thoughts or attempted suicide after BZD discontinuation.”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients have also reported that their withdrawal symptoms were often ignored, misattributed to recurrence of the conditions for which the BZD was initially prescribed, or misdiagnosed as another condition.128,200”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [128]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some patients may experience protracted symptoms of withdrawal after BZD discontinuation (see Box 6).81,128”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“Patients have reported difficulty finding knowledgeable providers for BZD tapering.128,200”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [128]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Discussion/conclusion
“only 22.8% of respondents could abruptly discontinue benzodiazepines”
§ Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey > Symptoms
“Of those who discontinued benzodiazepines, 5.2% reported they ‘withdrew just fine without taper’ and 17.6% said they ‘did not taper, quit abruptly but with consequences’.”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Consensus-Based Checklist for Reporting of Survey Studies (CROSS)
Sharma, A., Minh Duc, N. T., Luu Lam Thang, T., Nam, N. H., Ng, S. J., Abbas, K. S., Huy, N. T., Marušić, A., Paul, C. L., Kwok, J., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06737-1 · Cited by 2,292
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Principles of pharmacology : the pathophysiologic basis of drug therapy
Golan, D. E., & Tashjian, A. H. (2012) · Cited by 469
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Finney Rutten, L. J., Blake, K. D., Greenberg-Worisek, A. J., Allen, S. V., Moser, R. P., & Hesse, B. W. (2019) · Public Health Reports® · doi:10.1177/0033354919874074 · Cited by 426
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Cited by
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 94
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“…1,200 individuals recruited through several patient-facing internet and social media sites with content tailored to patients facing challenges with BZD discontinuation, Reid Finlayson et al. 128 found that 54% of respondents reported suicidal thoughts or attempted suicide after BZD discontinuation.”
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38
“Patients in our survey sometimes wrote in comments that they felt like healthcare professionals did not take them seriously or frankly challenged or disbelieved their long-lasting symptoms [9].”
BackgroundResultInfluentialSelf-citationHorowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 23
Moncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100765 · Cited by 20
Metadata
- Authors
- Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R.
- Affiliations
- Department of Psychiatry and Behavioral Sciences, Vanderbilt Psychiatric Hospital, Vanderbilt University Medical Center, Suite 3010, 1601 23rd Avenue South, Nashville, TN 37212, USA
- University of Southern California (US)
- Benzodiazepine Information Coalition, Midvale, UT, USA
- Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, CO, USA
- Vanderbilt University Medical Center (US)
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 12
- Pages
- 20451253221082386-20451253221082386
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC9047812
- OpenAlex
- W4225985734
- Semantic Scholar
- adbe676ec3739eb46fd3cc910edc6ba8c80f8814
- Cited by
- 40
- References
- 21
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 7 · 2023: 10 · 2022: 2
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, benzodiazepine tapering, benzodiazepine discontinuation, long-term benzodiazepine use, patient experience, suicidal ideation, employment problems, food allergy, seasonal allergy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. https://app.cochat.ai/papers/10.1177/20451253221082386
- The paper
- Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022). Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253221082386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.